Valeritas Holdings Partnership Announcement

Auckland, NZ, April 2018

NZMS Diabetes announces distribution agreement with Valeritas Holdings, Inc.                                                                            

NZMS Diabetes are pleased to announce they have signed an exclusive distribution agreement with Valeritas Holdings (NASDAQ: VLRX), a medical technology company which offers patients with type 2 diabetes products to help their day to day insulin management. Under the terms of the agreement, NZMS Diabetes will have the rights to promote, market and sell certain Valeritas products to diabetes clinics and patients within New Zealand.

“We are excited to offer our products to patients with type 2 diabetes in New Zealand, and thrilled to be partnered with NZMS Diabetes,” said John Timberlake, CEO and President of Valeritas. “Our decision to partner with NZMS Diabetes was driven by our goal of choosing the best distributor in New Zealand.”

“Our agreement with Valeritas is a significant step towards addressing the needs of NZ patients with type 2 diabetes who want simple and effective insulin management that doesn’t interfere with their way of life,” said Richard Plowright, Managing Director of NZMS. “We’re delighted with our exclusive partnership with Valeritas, and we’re looking forward to seeing the benefits it will bring to patients across NZ.”

Valeritas will retain responsibility for product development, regulatory approval, quality management and manufacturing while NZMS Diabetes will be responsible for sales, marketing, customer support and distribution activities within Australia.

About Valeritas Holdings
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercialising innovative technologies. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.